Cognition Therapeutics Inc (CGTX) stock
CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.63−0.01 (-1.39%)
Close on Nov 17, 2026Market cap $59.90MP/E –Yield –
Cognition Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Cognition Therapeutics's total assets was $38.90M at Jun 30, 2026. For fiscal 2025 it was $48.39M, up 60.1% from the year before. The highest annual figure on record is $59.14M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.39M | +60.1% |
| FY2024 | Dec 31, 2024 | $30.23M | -14.0% |
| FY2023 | Dec 31, 2023 | $35.16M | -30.3% |
| FY2022 | Dec 31, 2022 | $50.43M | -14.7% |
| FY2021 | Dec 31, 2021 | $59.14M | +730.7% |
| FY2020 | Dec 31, 2020 | $7.12M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $38.90M | +98.2% |
| Q1 FY2026 | Mar 31, 2026 | $36.14M | +53.8% |
| Q4 FY2025 | Dec 31, 2025 | $48.39M | +60.1% |
| Q3 FY2025 | Sep 30, 2025 | $43.40M | +57.3% |
| Q2 FY2025 | Jun 30, 2025 | $19.62M | -42.9% |
| Q1 FY2025 | Mar 31, 2025 | $23.50M | -39.5% |
| Q4 FY2024 | Dec 31, 2024 | $30.23M | -14.0% |
| Q3 FY2024 | Sep 30, 2024 | $27.58M | -28.9% |
| Q2 FY2024 | Jun 30, 2024 | $34.37M | -21.8% |
| Q1 FY2024 | Mar 31, 2024 | $38.85M | -14.9% |
| Q4 FY2023 | Dec 31, 2023 | $35.16M | -30.3% |
| Q3 FY2023 | Sep 30, 2023 | $38.77M | -27.6% |
| Q2 FY2023 | Jun 30, 2023 | $43.96M | -16.8% |
| Q1 FY2023 | Mar 31, 2023 | $45.66M | -22.2% |
| Q4 FY2022 | Dec 31, 2022 | $50.43M | -14.7% |
| Q3 FY2022 | Sep 30, 2022 | $53.56M | +300.0% |
| Q2 FY2022 | Jun 30, 2022 | $52.81M | +641.8% |
| Q1 FY2022 | Mar 31, 2022 | $58.70M | – |
| Q4 FY2021 | Dec 31, 2021 | $59.14M | – |
| Q3 FY2021 | Sep 30, 2021 | $13.39M | – |
| Q4 FY2020 | Dec 31, 2020 | $7.12M | – |
See a number that looks wrong?